<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706224</url>
  </required_header>
  <id_info>
    <org_study_id>115539</org_study_id>
    <nct_id>NCT01706224</nct_id>
  </id_info>
  <brief_title>Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals</brief_title>
  <official_title>Sero-prevalence of Pertussis Antibodies and Disease Awareness Among Healthcare Professionals in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study aims to determine the sero-prevalence of anti-pertussis antibodies among
      healthcare professionals at hospital centres in Spain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-pertussis (anti-PT) antibody levels.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-PT seropositivity status.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-PT seronegativity status.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the sero-prevalence of B. pertussis antibodies among healthcare professionals aged ≥ 18 years.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
    <description>By age and gender, by type of healthcare professional, by hospital department of the healthcare professional, duration of service and time spent with patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the sero-prevalence of anti-pertussis antibodies among healthcare professionals by vaccination history.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the sero-prevalence of anti-pertussis antibodies among healthcare professionals by previous history of pertussis.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the knowledge and beliefs about whooping cough and vaccination against pertussis among healthcare professionals.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the household composition of healthcare professionals to identify the proportion of healthcare professionals potentially at a higher risk of contracting and transmitting pertussis.</measure>
    <time_frame>Day 0 of each subject at the time of enrollment.</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">757</enrollment>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Subjects in this group will be all physicians actively working at hospital centres in Spain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Subjects in this group will be all nurses actively working at hospital centres in Spain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <description>Subjects in this group will be all midwives actively working at hospital centres in Spain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Samples will be tested to determine the presence of anti-pertussis antibodies.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Electronic Case Report Forms (eCRF)</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Questionnaires, active questioning.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthcare professionals actively working and involved with patient care in Spanish
        hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from the subject.

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  Male and female healthcare professionals aged ≥18 years from selected hospitals.

          -  Healthcare professionals in frequent contact with patients in the hospitals.

          -  Agreeing for collection of a blood sample for the study.

        Exclusion Criteria:

        • Medical students working as healthcare professionals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pertussis antibodies</keyword>
  <keyword>Bordetella pertussis</keyword>
  <keyword>sero-prevalence</keyword>
  <keyword>Healthcare professionals (HCP)</keyword>
  <keyword>Spain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

